|Bid||22.07 x 2500|
|Ask||22.08 x 800|
|Day's Range||20.41 - 22.15|
|52 Week Range||8.31 - 22.15|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|
Shares of Valeant Pharmaceuticals International (VRX) are higher Tuesday, and have easily outperformed this year, to the point that shorts may be throwing in the towel. Today, Cantor Fitzgerald's Louise Chen and her team write that the company has also seen the largest decrease in short interest in her coverage universe as of the end of November. The move comes as Valeant rose from less than $15 in mid-month to nearly $22 today.
Canada's main stock index rose on Tuesday, led by gains in drugmaker Valeant Pharmaceuticals and in the financial services sector. * At 10:18AM ET , the Toronto Stock Exchange's S&P/TSX composite index ...
U.S. stock futures are trending cautiously higher this morning, as focus remains on the Federal Reserve and the central bank’s interest rate policy. Against this backdrop, Dow Jones Industrial Average futures are up 0.18%, S&P 500 futures have added 0.10% and Nasdaq-100 futures are higher by 0.02%. Taking a closer look at Monday’s options activity, Tesla Inc (NASDAQ:TSLA) calls and puts were active as reports emerged that “hundreds” of Model 3s are now showing up at delivery centers.
Every day on PreMarket Prep, hosts Joel Elconin and Dennis Dick highlight over a dozen key morning movers to keep an eye on throughout the day. Below is a trade we thought is particularly hot today. Valeant ...
The Vetr crowd on Thursday upgraded its rating on Valeant Pharmaceuticals International, Inc. (NYSE: VRX ), from 4 stars (Buy), issued two days ago, to 5 stars. Crowd sentiment at the time of the upgrade ...
NEW YORK, NY / ACCESSWIRE / December 7, 2017 / Immunomedics soared yesterday after revealing positive data from a phase 2 study on its lead compound that could treat metastatic triple-negative breast cancer. ...
LAVAL, Quebec , Dec. 7, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced that Scott A. Hirsch , senior vice president and ...
Valeant To Participate At The BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference
After a big run through September, Shopify Inc (US)(NYSE:SHOP) stock has lost some of its mojo. Might there be an opportunity with SHOP stock? One reason is the attack from short seller Andrew Left, who operates Citron Research.
Two years ago, Valeant Pharmaceuticals International Inc. shares plunged off a cliff. Now, some investors are starting to pick them up and dust them off.
Billionaire investor Bill Ackman’s audacious partnership with Valeant Pharmaceuticals International Inc. to make a hostile bid for drug company Allergan Inc. in 2014 brought him a windfall of more than ...
Jim Simons, the founder of one of the world's most successful hedge funds, is splashing out on controversial healthcare stock Valeant Pharmaceuticals (NYSE:VRX). However, this fund guru is displaying a more cautious attitude towards Opko Health (NASDAQ:OPK). Will these moves take his $85 billion fund to new heights?
Valeant Pharmaceuticals sees its Relative Strength Rating move into the elite 90-plus level.
LAVAL, Quebec, Dec. 4, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (VRX) (VRX) ("Valeant" or the "Company") announced today that it has priced its previously announced offering of 9.000% senior notes due 2025 (the "Notes"). Valeant intends to use the net proceeds from this offering, along with cash on hand, to repurchase $1,500,000,000 aggregate principal amount of outstanding notes pursuant to a tender offer announced earlier today, including Valeant Pharmaceuticals International's, a wholly-owned subsidiary of the Company, outstanding 7.000% Senior Notes due 2020 and 6.375% Senior Notes due 2020 and up to $200,000,000 of the Company's outstanding 5.375% Senior Notes due 2020, and to pay related fees and expenses. The Notes will be guaranteed by each of the Company's subsidiaries that are guarantors under the Company's credit agreement and the Company's existing senior notes.
Valeant And One Of Its Subsidiaries Announce Upsize Of Cash Tender Offers To $1,500,000,000 Outstanding Principal Amount
The Company and VPI announced that they have increased the maximum aggregate principal amount of Notes that may be purchased (the "Aggregate Maximum Purchase Amount") pursuant to the Tender Offers from $1,000,000,000 to $1,500,000,000. No more than $200,000,000 aggregate principal amount (the "Tender Cap") of 5.375% Senior Notes due 2020 (the "5.375% Notes" or the "Priority 3 Notes") will be purchased in the Tender Offers.
Stocks are weak out of the gate again, with the tech-heavy Nasdaq down the most. In addition to the tax bill making its way through Congress, we just got the ADP numbers this morning showing private companies added added 190,000 jobs in November. Moody's Mark Zandi warning the job market will be overheated next year. Yahoo Finance's Alexis Christoforous and Jared Blikre discuss.